Medacta Group (FRA:6MD) OCF Margin %: 23.46% (As of Dec. 2025) — 24% Above Median


FRA:6MD Medacta Group SA FRA:6MD
91 GF Score
Price €143.00
GF Value €178.79
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Medacta Group OCF Margin %?

Medacta Group FRA:6MD +1.42% 91 OCF Margin % is 23.46% as of Dec. 2025, which is 24% above its 10-year median of 18.92. GuruFocus rates FRA:6MD with a GF Score™ of 91/100 and a GF Value™ of €178.79 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Medacta Group ranks better than 84.66% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Medacta Group's Cash Flow from Operations for the six months ended in Dec. 2025 was €79.7 Mil. Medacta Group's Revenue for the six months ended in Dec. 2025 was €339.7 Mil. Therefore, Medacta Group's OCF Margin % for the quarter that ended in Dec. 2025 was 23.46%.

As of today, Medacta Group's current OCF Yield % is 5.36%.

The historical rank and industry rank for Medacta Group's OCF Margin % or its related term are showing as below:

FRA:6MD' s OCF Margin % Range Over the Past 10 Years
Min: 13.73   Med: 18.92   Max: 25.71
Current: 22.32


During the past 11 years, the highest OCF Margin % of Medacta Group was 25.71%. The lowest was 13.73%. And the median was 18.92%.

FRA:6MD's OCF Margin % is ranked better than
84.66% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: 5.86 vs FRA:6MD: 22.32


Medacta Group OCF Margin % Related Terms


Medacta Group OCF Margin % Historical Data

* Premium members only.

The historical data trend for Medacta Group's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medacta Group OCF Margin % Chart

Medacta Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.89 16.82 14.71 18.14 22.32

Medacta Group Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.73 14.50 21.63 21.20 23.46

FRA:6MD vs ABT, SYK, MDT: OCF Margin % Comparison

For the Medical Devices subindustry, Medacta Group's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medacta Group OCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's OCF Margin % distribution charts can be found below:

* The bar in red indicates where Medacta Group's OCF Margin % falls into.


FRA:6MD
91GF Score
Medacta Group SA FRA:6MD
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medacta Group OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Medacta Group's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=152.653/683.827
=22.32 %

Medacta Group's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=79.701/339.687
=23.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 23.46% mean?
Medacta Group (FRA:6MD) has a OCF Margin % of 23.46% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medacta Group and its competitors. This is 24% above median its historical median of 18.92. Over the past decade, Medacta Group's OCF Margin % has ranged from 13.73 to 25.71. According to the industry distribution chart, Medacta Group ranks #125 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 15.3%.
Is Medacta Group's OCF Margin % too high?
Medacta Group's current OCF Margin % of 23.46% is 24% above median its 10-year median of 18.92. Over the past 10 years, this metric has ranged from a low of 13.73 to a high of 25.71. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Medacta Group's value of 23.46% is 300.3% above this industry median. Based on the distribution chart, Medacta Group ranks #125 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medacta Group has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medacta Group's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medacta Group ranks #125 out of 815 companies for OCF Margin %. This places Medacta Group in the top 15% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 5.86. Medacta Group's value of 23.46% is 300.3% above this benchmark. Historically, Medacta Group's own OCF Margin % has ranged from 13.73 to 25.71 over the past decade. While the company's 10-year median is 18.92 vs. the industry median of 5.86, Medacta Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medacta Group's current OCF Margin % of 23.46% is 300.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Medacta Group and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medacta Group's current OCF Margin % is 23.46%, which is 24% above median its own 10-year median of 18.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medacta Group stock overvalued right now?
Based on GuruFocus' analysis, Medacta Group (FRA:6MD) is currently considered Modestly Undervalued. The stock's GF Value™ is €178.79, compared to a current price of €143.00 — trading 20% below its estimated fair value. The current OCF Margin % is 23.46%, which is 24% above median its 10-year median of 18.92 and 300.3% above the Medical Devices & Instruments industry median of 5.86. Medacta Group's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Medacta Group (FRA:6MD), the current OCF Margin % is 23.46% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medacta Group (FRA:6MD) Overvalued in 2026?

Based on GuruFocus' analysis, Medacta Group stock appears to be undervalued. The current stock price of €143.00 is trading 20% below its estimated GF Value™ of €178.79. GuruFocus considers Medacta Group to be Modestly Undervalued.

Key valuation signals for FRA:6MD:

  • OCF Margin %: 23.46% (24% above median its 10-year median of 18.92)
  • GF Value™: €178.79 vs. price of €143.00 (20% below fair value)
  • GF Score™: 91/100 with 2 warning signs
  • Industry Position: 300.3% above the Medical Devices & Instruments median (#125 of 815)

No single metric tells the full story. See the FRA:6MD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medacta Group Business Description

Address Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is involved in developing, manufacturing, and distributing orthopedic and neurosurgical medical devices. It specializes in the design, production, and distribution of personalized and sustainable solutions for joint replacement, sports medicine, and spine surgery. Medacta's product portfolio includes hip, knee, shoulder, and spine replacement solutions, along with a comprehensive range of sports medicine. Its products and surgical techniques are supported by an extensive program of surgeon education and engagement initiatives, enabling its offerings to be effective for the patient and surgeon. Geographically, the company derives maximum revenue from EMEA (which includes Europe, Middle East and Africa), followed by North America, Asia-Pacific, and the Latin America markets.
91GF Score

Get the complete analysis for FRA:6MD

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€143.00
Price
€178.79
GF Value